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Abstract: This study used an integrated approach to investigate the effects of Gymnema
sylvestre (GS) extract as a functional dietary supplement with a high-fat diet. This approach
examined insulin resistance, the dysfunction of adipose tissue, and liver steatosis. Male
C57BL/6J mice were fed a normal chow or high-fat diet (HFD) for the acute and chronic
study, in addition to GS in different doses (100, 250 and 500mg/kg body weight). Their body
composition changes, serum lipid and glucose parameters, adipose and liver tissue histology,
and gene expression were measured. It was found that GS significantly suppressed the
increase of body weight, serum levels of lipid, insulin and leptin, and adipose tissue, and
liver inflammation. GS also demonstrated hypoglycemic effects due to the amylase inhibition
activity. Our results support the existence of a relationship between the HFD induced insulin
resistance, adipose dysfunction and liver steatosis. In conclusion, GS works as a functional
dietary supplement with preventative effects against metabolic disorder.
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Obesity is associated with various metabolic disorders such as insulin resistance, diabetes,
hypertension, stroke, cardiovascular disease, and nonalcoholic fatty liver disease
(NAFLD), (Pothuraju et al., 2013; van der Heijden et al., 2015). Among the numerous
causes of obesity, nutrient overload due to an increased intake of a high-fat diet (HFD) is
regarded as a prominent factor that causes an imbalance between energy intake and ex-
penditure (Strauss et al., 2000; Li et al., 2013; Gao et al., 2015). For this reason,
HFD-induced obesity in rodents is considered a good model to study metabolic disorders
including adiposity, hepatic lipid accumulation and insulin resistance (Bhutani et al., 2007;
Jin et al., 2013; Tanaka et al., 2015).
Over the last two decades, knowledge regarding obesity-induced insulin resistance has
improved significantly; it has been found that the disorder is closely related to the path-
ogenesis of type 2 diabetes, adipocyte dysfunction and NAFLD (Begriche et al., 2013).
Dysfunction of adipose tissue causes metabolic disruption in energy homeostasis as well as
an energy imbalance, and plays a role in NAFLD development and progression (Gastaldelli
et al., 2009; Duval et al., 2010). In addition, chronic inflammation characterized by
macrophage infiltration or excessive lipid accumulation in adipocytes contributes to
hypertrophied adipocytes. The latter lead to changes in the secretion levels of adipokines
such as adiponectin and leptin. These pathological conditions are strongly linked to insulin
resistance in obesity (Lumeng and Saltiel, 2011; Jiang et al., 2011).
As noted, the changed metabolic state of the liver depends on the rise of insulin
resistance and the inflammation of adipose tissue. With these changes, the liver can gain
hepatic dysfunction such as NAFLD. The liver is well known for its ability to regulate
energy homeostasis and systemic metabolic balance. However, pro-inflammatory activa-
tion of Kuffer cells is induced by the consumption of a HFD, and can lead to obesity-
induced liver disease and insulin resistance (Asai et al., 2014; van der Heijden et al., 2015).
Thus, insulin resistance, adipose dysfunction and NAFLD are correlated with HFD-
induced obesity (Asai et al., 2014; García-Ruiz et al., 2015).
At present, natural herbal resources with biological activities have been widely inves-
tigated as anti-obesity and antidiabetic agents. Gymnema sylvestre (GS) is a woody climber
of the Asclepiadaceae family, and is mainly found in the tropical regions in the world
(Leach, 2007). It is well known for its antihypercholesterolemia, anti-inflammatory and
antimicrobial properties, in addition to its well-studied antidiabetic and anti-obesity effects
(Vermaak et al., 2011; Tiwari et al., 2014; Kishore et al., 2014). In many phytochemical
analyses, GS is known to include gymnemic acids, stigmasterol, quercitol and amino acids
derivative of betaine, ethylamine and choline. One of the major active compounds is
gymnemic acids and found in all parts of the plant. This mechanism is known to stimulate
insulin secretion from the pancreas and to delay the absorption of glucose into the blood. In
addition, other compounds also have a similar effect; however, they have less pervasive
antisweet effects than gymnemic acids do (Tiwari et al., 2014; Kishore et al., 2014).
In previous studies, the administration of GS (120mg/kg/day) for seven days in
streptozotocin (STZ)-treated diabetic mice increased the regeneration and function of









































































































β-cells in pancreatic islets, resulting in higher serum levels of C-peptide (Shanmugasundaram
et al., 1990). Oral administration of GS also decreased the levels of blood glucose,
glycated hemoglobin, and free fatty acid, while increasing insulin levels in STZ-treated
diabetic rats (Daisy et al., 2009; Kosaraju et al., 2014). In addition, GS exhibited anti-
obesity effects through decreased body weight gain and the serum levels of total cholesterol
(TC), triglycerides (TG) and low-density lipoprotein (LDL)-cholesterol, (Shigematsu et al.,
2001; Reddy et al., 2012; Kumar et al., 2013). Many scientific studies involving GS,
however, have been performed using mutant mice or rats such as db/db, ob/db, and STZ-
treated diabetic models, and have not used oral administration.
In our previous studies, we made a mixed-feed containing HFD and GS that was used
for 4 weeks. GS showed significant anti-obesity effects in comparison to only a HFD, but
the hypoglycemic effect was insufficient (Kim et al., 2016). Therefore, the objective of this
study is to evaluate the acute and chronic antiobesity and antidiabetic effects of GS using
correlated analyses of insulin resistance and the dysfunction of adipose tissue and the liver.
Materials and Methods
Extraction and Phytochemical Analysis of GS
The extract of GS was obtained from TC, TG, LDL-cholestrol in powder form and stored at
4C until usage. To identify the amount of gymnemic acid in GS, HPLC and gravimetric
analysis were performed. Extraction and HPLC were performed based on previous
methods (Kusum et al., 2014). The HPLC chromatogram for deacyl gymnemic acid is
shown in Fig. S1, and the profile is described in Table S1.
Animal Experiments
Male C57BL/6J mice were purchased from Central Lab Animal Co. (Seoul, Korea), and
housed under a 12-h dark/light cycle. All animal experiments were performed in accor-
dance with the Seoul National University Animal Ethics Committee protocol
(SNU-150829-3). After one week of acclimation on a normal chow (D12450K; Research
Diets, New Brunswick, NJ, USA), animals were randomly divided. First, for acute study,
mice were divided into 4 groups (n ¼ 5, 7 weeks old): (i) a control (CON) group that
received water, and three groups that received a single oral administration of GS, (ii) at
100mg/kg body weight, (iii) at 250mg/kg body weight and (iv) at 500mg/kg body weight.
Animals fed a normal chow in this experiment. Second, to evaluate the chronic effects,
mice were divided into 5 groups (n ¼ 10, 7 weeks old): (i) a control (CON) group fed a
normal chow, (ii) a HFD group, a group fed a HFD plus GS, (iii) at 100mg/kg body weight
(HFDþGS 100mg/kg group), (iv) at 250mg/kg body weight (HFDþGS 250mg/kg group)
and (v) at 500mg/kg body weight (HFDþGS 500 mg/kg group). The HFD contained 60%
kcal fat (D12492; Research Diets), and all groups were fed the diet for 8 weeks. The
detailed dietary composition is shown in Table S2. Body weight and food intake were
assessed twice per week during the experimental period. Based on these measurements,









































































































food efficiency ratio (increased body weight (g)/food intake (g)) and energy efficiency ratio
(increased body weight (g)/energy intake (kcal)) were calculated.
Biochemical Analysis
Serum TC, TG, creatine, total protein, aspartate aminotransferase (AST), and alanine trans-
aminase (ALT) levels were analyzed by the Preclinical Research Center (ChemOn, Inc.,
Gyeonggi-do, Korea). High-density lipoprotein (HDL)-cholesterol, LDL/very low-density
lipoprotein (VLDL)-cholesterol, leptin, insulin, HbA1c, liver TG were measured with a
commercial ELISA kit. Amylase activity was measured measured by serum after acute study
of GS. All procedures were performed following the manufacturer’s instructions.
Histological Analysis
The adipose tissues and liver samples were fixed in 10% neutral buffered formalin, paraffin
processed, and sectioned at 5 μm. Paraffin-embedded sections were stained with hema-
toxylin and eosin (H&E) and Picrosirius Red according to the manufacturer’s protocols,
and then examined under a light microscope (Nikon Eclipse Ti; Nikon, Tokyo, Japan). The
number and size of adipocytes and collagen deposition in the liver tissue were measured by
using Image J Software (version 1.48; National Institutes of Health, Bethesda, MD, USA).
The NAFLD activity score (NAS) data were analyzed based on the following histologic
data: diagnosis rendered by the Pathology Committee (i.e. “not steatohepatitis”, “border-
line, zone 3 pattern”, “definite steatohepatitis”); the aggregate NAS; the score of each
component of the NAS (steatosis (0–3), lobular inflammation (0–3), ballooning (0–2)), and
fibrosis scores (0,1a,1b,1c,2,3).
Oil Red O Staining
Liver tissues were fixed in 4% paraformaldehyde solution at 4C for one day, transferred to
10%, 20%, and 30% sucrose solutions for one day each, and then embedded with Tissue-
Tek OCT (Sakura, Torrance, CA, USA). The tissues were sectioned at 8 μm and stained
with 0.5% Oil red O stock solution in propylene glycol (O1516, Sigma-Aldrich) for 10min
at 56C, and then counterstained with Mayer’s hematoxylin.
Glucose and Insulin Tolerance Tests
The intraperitoneal glucose tolerance test (IPGTT) and insulin tolerance test (ITT) were
performed. For IPGTT, animals were fasted overnight and 1.5 g/kg body weight of glucose
was administered by intraperitoneal injection. Using intraperitoneal injection, an ITT was
performed after fasting for 6 h, using human insulin HI-0310 (Lilly, Indianapolis, USA) at
a body weight of 0.75U/kg. At the time points indicated, blood glucose concentrations
were measured with an Accu-Chek glucometer (Roche, Basel, Switzerland).









































































































Postprandial Glucose Test for Acute Study of GS
The postprandial glucose test was performed after a single oral administration of GS.
Animals were put into a postprandial state with an intraperitoneal injection of glucose
(1.5 g/kg body weight), and then a single oral administration of GS (100, 250, 500mg/kg
body weight) was performed after 10min. At the time points indicated, blood glucose
concentrations were measured.
Western Blotting
Western blotting was performed based on previous methods (Yu et al., 2016), and
membranes were immunoblotted with primary antibodies, specifically α-SMA (ab5694),
UCP1 (ab10983) antibodies (Abcam, Cambridge, MA, USA), AMPKα (#2532) and
pAMPKα (#2535) antibodies (Cell Signaling, Danvers, MA, USA), NF-κB (sc-372), p38
(sc-7942) and ß-actin (sc-1616HRP) antibodies (Santa Cruz Biotechnology, CA, USA).
Secondary antibodies were conjugated to horseradish peroxide for 2 h at room temperature,
rinsed and detected using an ATTO CS image analyzer 3.0 (ATTO, Tokyo, Japan).
RNA isolation and Real Time Quantitative Polymerase Chain Reaction
Total RNA was extracted by using the QuickGene RNA tissue kit SII (Fujifilm, Tokyo,
Japan), and cDNA was synthesized with the Suprime script RT premix (GeNet Bio,
Daejeon, Korea), according to the manufacturer’s instructions. Quantitative Polymerase
Chain Reaction was performed with the CFX96 real time system (Bio-Rad, Hercules, CA),
and each cDNA was amplified with the Q-master mix (Genet Bio, Daejeon, Korea). The
designed primers are shown in Table S3. We used Manager Version 2.1 Software (Bio-
Rad) to analyze the data.
Immunohistochemistry
Primary F4/80 antibody (PA5-32399, Thermo Fisher Scientific) and UCP-1 (ab10983,
Abcam) were used for immunohistochemistry (IHC) and performed according to the
previous method (Yu et al., 2016). The slides were observed using a light microscope
(Eclips Ti-S, Nikon, Tokyo, Japan). Counting the number of positive cells and measuring
intensity in randomly selected field images were performed using the Image J Software
(Version 1.48; National Institutes of Health).
Statistical Analyses
Results are shown as the mean  SEM. One-way analysis of variance (ANOVA) with
a post hoc Student-Newman-Keuls multiple comparison test was performed using
GraphPad (San Diego, CA, USA). IPGTT, ITT and a postprandial glucose tests were









































































































statistically compared using a two-way repeated-measures ANOVA with a Bon-
ferroni post hoc test (GraphPad). All results were considered statistically significant
at p < 0:05.
Results
Effects of GS on Body Composition
The characteristics of the mice were determined in Table 1. The total body weight gain
showed significant increases with a HFD, whereas GS significantly reduced the weight
gain. Food intake decreased in the HFDþGS 500mg/kg group, but this was due to bitter
taste of GS. Food and energy efficiency ratios were significantly decreased in all con-
centrations of GS. Increased organ weight in the liver and white adipose tissue was also
closely related to body weight gain, and the HFD group showed significant increases in the
organ weight whereas these values were significantly decreased in the GS groups. These
results suggest that the consumption of GS influenced the body weight gain induced by a
HFD and led to a decreased food and energy efficiency ratio.
Table 1. Characteristics of Mice After 8-week Experimental Period
HFD+GS(mg/kg)
CON HFD 100 250 500
Initial BW (g) 25:38 0:42 26:08 0:44 24:85 0:28 24:63 0:53 24:88 0:35
Final BW (g) 31:60 0:57 41:79 1:70*** 37:49 1:08**, †† 37:45 0:66**, † 37:35 1:09***, †
ΔBW (g) 6:22 0:24 15:72 1:29*** 12:64 0:82***, † 12:83 0:15***, † 12:47 0:75***, †
Food intake (kcal/
day/mouse)
13:76 1:53 16:54 1:29** 15:56 2:06 15:65 0:99 14:77 1:35††
Total energy in-
take (kcal)
780:35 95:60 893:48 105:35 882:73 126:77 876:51 55:33 853:22 101:92
Food efficiency
(%)
3:11 0:25 9:66 2:65*** 7:23 0:88***, †† 7:32 0:32***, † 7:32 1:72***, †
Energy efficiency
(mg/kcal)
7:70 1:00 18:75 3:35*** 12:55 4:85***, † 14:10 1:00***, †† 13:95 3:25***, ††
Organ weight
Liver weight (g) 1:03 0:01 1:45 0:03*** 1:29 0:03***, ††† 1:27 0:04***, ††† 1:32 0:02***, ††
Epididymal fat
weight (g)
0:79 0:23 3:49 0:67*** 2:80 0:45***, †† 2:59 0:44***, ††† 2:54 0:48***, †††
Peritoneal fat
weight (g)




3:39 0:82 10:82 1:46*** 10:13 2:54*** 9:20 1:59***, † 10:00 2:30***, †
Notes: All values are mean  SEM. (n ¼ 810) **p < 0:01, ***p < 0:001 versus control (CON) group,
†p < 0:05, ††p < 0:01, †††p < 0:001 versus high-fat diet (HFD) group.









































































































Effects of GS on Glucose Homeostasis and Insulin Resistance
All HFDþGS groups showed significant decreases in the level of final fasting glucose,
serum insulin, HOMA-IR and glycated hemoglobin (HbA1c) in the HFD group (Table 2).
To further examine metabolic changes, we performed an IPGTT and ITT, finding that GS
induced significantly lower glucose levels, as confirmed by the area under the curve
(Figs. 1A and 1B). Additionally, to measure whether the single oral administration of GS
also affects hyperglycemia, a postprandial glucose test and ITT were performed. At all
concentrations of GS, glucose levels were significantly decreased relative to the CON
group, as can be seen at 30, 60 and 90min time marks (Fig. 1C). ITT also showed
significant decreases at 60, 90 and 120min in comparison to the CON group, as confirmed
by the AUC (Fig. 1D). In addition, GS significantly reduced amylase activity at all con-
centrations (Fig. 1E). These results indicated that GS could ameliorate glucose intolerance
and insulin resistance, decreasing postprandial glucose level by inhibiting amylase activity.
Effect of GS on Serum Levels of Lipid Parameters
The consumption of a HFD for 8 weeks induced marked elevation of serum TC, TG, LDL/
VLDL-cholesterol, total protein and creatine, but also reduced HDL-cholesterol levels
(Table 3). However, GS significantly decreased serum TC, TG, LDL/VLDL-cholesterol
levels in comparison to the HFD group. In comparison to the CON group, the serum HDL-
cholesterol level was significantly decreased in the HFD and HFDþGS 100mg/kg groups,
however, there were no significant changes in other groups. Serum creatine levels showed
no significant differences among all groups.
Table 2. Effect of GS on the Glucose Homeostasis and Insulin Resistance
HFD+GS(mg/kg)








81:88 0:98 139:17 11:33*** 114:00 4:62**, † 108:86 3:56**, †† 112:86 5:30**, †
Serum insulin
(ng/ml)
0:11 0:01 0:18 0:02* 0:13 0:02* 0:10 0:01† 0:11 0:01†
HOMA-IR1Þ 0:59 0:06 1:77 0:30** 0:93 0:17†† 0:70 0:11†† 0:72 0:11††
Insulin sensitivity2Þ 1:74 0:17 0:60 0:10* 1:19 0:23 1:55 0:25† 1:47 0:19†
HbA1c (%) 3:66 0:13 4:80 0:38* 4:12 0:22 4:16 0:08 3:87 0:12†
Notes: All values are mean  SEM (n ¼ 57). *p < 0:05, **p < 0:01, ***p < 0:001 versus control (CON)
group, †p < 0:05, ††p < 0:01 versus high-fat diet (HFD) group.
(i) HOMA-IR was calculated as follows: glucose (mmol/L)  fasting insulin (μIU/mL)/22.5.
(ii) Insulin sensitivity was calculated as follows: 1/HOMA-IR.









































































































Effects of GS on Adiposity and Inflammation in White Adipose Tissue
Next, we questioned whether the previously beneficial effects of GS were related to adipose
tissue. To test this, H&E staining and F4/80 IHC were performed (Fig. 2A). GS signifi-
cantly increased the cell density (Fig. 2B), and the adipocyte mean area also significantly
increased in comparison to the HFD group (Fig. 2C). The cells positive for F4/80 exhibited
crown-like structures in the white adipose tissue (black arrow; Fig. 2A). An HFD induced a
significant increase in macrophage (F4/80þ) infiltration relative to the CON group, how-
ever, GS significantly reduced it (Fig. 2D). GS also effectively decreased NF-κB and p38
protein levels (Fig. 2E) and the mRNA expression of TNF-α and SREBP-1c in comparison
Figure 1. Effects of Gymnema sylvestre extract on glucose intolerance and insulin resistance. (A) Intraperitoneal
glucose tolerance test (IPGTT) after 8 weeks and the area under the curve (AUC), (B) insulin tolerance test (ITT)
after 8 weeks and the AUC, (C) postprandial glucose levels after single oral administration in normal C57BL/6J
mice and the AUC, (D) insulin tolerance test (ITT) after single oral administration in normal C57BL/6J mice and
the AUC and (E) amylase activity. Values are mean  SEM. *p < 0:05, **p < 0:01, ***p < 0:001 versus control
(CON) group, #p < 0:05, ##p < 0:01 versus high-fat diet (HFD) group.









































































































to the HFD group (Fig. 2F). Therefore, these results indicated that GS could prevent the
adiposity and inflammation that is induced with the consumption of a HFD.
Effects of GS on Energy Homeostasis in White and Brown Adipose Tissue
To evaluate whether GS can regulate systemic energy homeostasis, UCP-1 IHC was
performed in white and brown adipose tissue (Fig. 3A). In white adipose tissue, the ex-
pression level in the HFDþGS 250mg/kg group was significantly higher in comparison to
the HFD and HFDþGS 100mg/kg groups (Fig. 3B). In addition, GS showed an increase in
the protein levels of UCP-1 in white adipose tissue in contrast to significantly decreased
protein levels in brown adipose tissue (Fig. 3C). With reduced the serum leptin levels
(Fig. 3D), the mRNA expression of leptin and adiponectin also showed significant effects
in white adipose tissue (Fig. 3E). These results suggest that GS could ameliorate energy
imbalance by regulating leptin and adiponectin levels in white adipose tissue.
Effects of GS on Lipid Accumulation in the Liver
After feeding on a HFD for 8 weeks, microvesicular steatosis and inflammatory cell
infiltration were observed with H&E and oil red O staining of liver slides (Fig. 4A). In the
histopathological examination, GS showed significantly lower scores (Fig. 4B), especially
with steatosis (Fig. 4C). With the changes of oil red O staining among the groups, the
amount of neutral lipids in the liver was also significantly elevated in the HFD group as
opposed to the GS-induced reduction (Fig. 4D). In addition, GS significantly elevated the
ratio of phosphorylation of AMPKα (Fig. 4E). The activities of the liver marker enzymes,
AST and ALT, were also significantly decreased (Figs. 4F and 4G). Consequently, these
Table 3. Serum Levels of Lipid
HFD+GS(mg/kg)
CON HFD 100 250 500
TC (mg/dl) 67:00 3:00 142:00 2:00*** 121:00 11:00***, † 107:00 23:00***, † 122:00 20:00***
TG (mg/dl) 41:00 7:00 62:00 20:00** 41:00 9:00†† 40:00 10:00†† 48:00 14:00††
HDL-cholesterol
(mg/dl)




4:36 1:36 19:58 6:13*** 18:21 7:95** 10:27 2:27† 10:04 2:50†
Creatine (mg/dl) 0:33 0:02 0:34 0:04 0:33 0:03 0:30 0:02 0:34 0:00
Total protein
(g/dl)
4:09 0:30 4:71 0:23** 4:62 0:34* 4:31 0:31 4:45 0:29*
Notes: All values are mean  SEM (n ¼ 57). *p < 0:05, **p < 0:01, ***p < 0:001 versus control (CON)
group, †p < 0:05, ††p < 0:01, †††p < 0:001 versus high-fat diet (HFD) group.









































































































results indicated that HFD triggered hepatic steatosis, but GS was able to significantly
ameliorate these effects.
Effects of GS on Hepatic Inflammation and Fibrosis
We confirmed that HFD induced hepatic steatosis through collagen deposition and in-
flammation in the liver. Hepatic collagen deposition was evaluated with Sirius red staining
(Fig. 5A) and the intensity was quantified (Fig. 5B). Macrophages in the liver were
Figure 2. Effects of Gymnema sylvestre extract on adiposity and inflammation in white adipose tissue. (A) White
adipose tissue stained with H&E and F4/80 IHC (black arrow: macrophage infiltration), (B) adipocyte density, (C)
adipocyte mean area, (D) quantitative assessment of F4/80-positive cells per total cell, (E) relative protein levels of
NF-κB, p38 and β-actin by western blot and densitometry, and (F) mRNA expression levels of TNF-α and
SREBP-1c by qRT-PCR. Scale bars ¼ 50 μm. Values are mean  SEM. *p < 0:05, **p < 0:01, ***p < 0:001
versus control (CON) group, #p < 0:05, ##p < 0:01, ###p < 0:001 versus high-fat diet (HFD) group,
$p < 0:05, $$p < 0:01, $$$p < 0:001 versus high-fat diet containing GS 100 mg/kg body weight (HFDþGS
100mg/kg) group.









































































































identified by F4/80 IHC (Fig. 5A) and the percent area was quantified (Fig. 5C).
In comparison to the CON group, the HFD group showed significant increases, while GS
showed significant decreases. Additionally, GS significantly decreased the protein levels of
α-SMA, NF-κB and p38 (Fig. 5E) as well as mRNA levels of TNF-α, TGF-ß, IL-6 and
FAS (Fig. 5F). These results indicated that GS could ameliorate liver inflammation and
fibrosis.
Figure 3. Effects of Gymnema sylvestre extract on energy homeostasis in white and brown adipose tissue.
(A) IHC of UCP-1 in white and brown adipose tissue, (B) quantitative assessment of UCP-1-positive ex-
pression in white adipose tissue and (C) relative protein levels UCP-1 and β-actin in white and brown adipose
tissue by Western blot and densutimetry, (D) serum leptin levels and (E) mRNA expression levels of leptin
and adiponectin in white adipose tissue. Scale bars¼ 100 μm. Values are mean  SEM. *p < 0:05,
**p < 0:01, ***p < 0:001 versus control (CON) group, #p < 0:05, ##p < 0:01 versus high-fat diet (HFD)
group, $p < 0:05 versus high-fat diet containing GS 100mg/kg body weight (HFDþGS 100mg/kg) group.










































































































The aim of this study is to investigate the anti-obesity and antidiabetic effects of GS as a
functional dietary supplement in cases of a HFD. Many metabolic disorders induced by
HFD are mainly related with insulin resistance, dysfunction of adipose tissue and liver. Our
present study focused on these correlations and identified the potential and effectiveness of
GS as a functional dietary supplement.
To study metabolic disorders caused by HFD, it is crucial to analyze the body com-
position (body weight gain, food and energy efficiency ratios and organ weight) and serum
Figure 4. Effects of Gymnema sylvestre extract on lipid accumulation in the liver. (A) Liver tissue stained with
H&E and oil-red O, (B) the non-alcoholic fatty liver disease (NAFLD) score, (C) separate scores for steatosis,
inflammation and ballooning, (D) total liver TG content after 8 weeks, (E) relative protein levels of pAMPKα,
AMPKα and β-actin by Western blot and densitometry, (F) serum AST level and (G) serum ALT level. Scale bars
¼ 100 μm. Values are mean  SEM. *p < 0:05, **p < 0:01, ***p < 0:001 versus control (CON) group,
#p < 0:05, ##p < 0:01, ###p < 0:001 versus high-fat diet (HFD) group.









































































































Figure 5. Effects of Gymnema sylvestre extract on hepatic inflammation and fibrosis. (A) Liver tissue stained with
Sirius red and F4/80 IHC, (B) intensity of Sirius red, (C) intensity of F4/80 IHC, (D) relative protein levels of
α-SMA, NF-κB, p38 and β-actin by Western blot, (E) Western blot densitometry, and (F) mRNA expression levels
of TNF-α, TGF-β, IL-6 and FAS by qRT-PCR. Scale bars ¼ 50 μm. Values are mean  SEM. *p < 0:05,
**p < 0:01, ***p < 0:001 versus control (CON) group, #p < 0:05, ##p < 0:01, ###p < 0:001 versus high-fat
diet (HFD) group, $$p < 0:01, $$$p < 0:001 versus high-fat diet containing GS 100mg/kg body weight
(HFDþGS 100mg/kg) group.









































































































levels of lipid (TC, TG, HDL- and LDL-cholesterol). In our present study, all groups fed
with GS showed significant decreases in regards to body weight gain, food and energy
efficiency ratios, and the organ relative to the HFD group. The food intake of HFDþGS
500mg/kg group was decreased in comparison to other groups; we expect this to be
attributable to an antisweet property of GS. In addition, GS effectively reduced the serum
levels lipid relative to the HFD group. Previous studies have shown that hyperglycemia and
insulin resistance are induced by a HFD, and have related glucose homeostasis and insulin
resistance to body weight loss and improved serum lipid levels (Choi et al., 2013). GS
could help promote body weight loss by controlling serum lipid parameters such as TC,
TG, in STZ diabetic or HFD induced models (Potawale et al., 2008; Kishore et al., 2014).
The exact mechanisms of how GS is able to improve these body composition and serum
lipid parameters have not yet been revealed. Some researchers have investigated the
mechanisms of GS; it may suppress the increase of blood glucose levels by inhibiting
glucose uptake in the intestine and increasing the secretion of insulin in the pancreas
(Potawale et al., 2008; Kishore et al., 2014). In our study, we confirmed that GS signifi-
cantly reduced the level of fasting glucose, serum insulin, and HOMA-IR and HbA1c after
the consumption of a HFD. Furthermore, the single oral administration of GS showed
antidiabetic effects in a postprandial state and this mechanism was based on the inhibition
of amylase activity. Amylases are enzymes that break down of disaccharide or oligo to
monosaccharides, and the inhibition of an amylase is known to cause a delayed digestion of
carbohydrates (Srinivasulu et al., 2016). This decreased activity suggests that GS could
decrease the rate of glucose absorption and regulate lipid level.
Adipose tissue is known to be an important site of inflammation, energy homeostasis
and for the maintenance of lipid flux (Tanaka et al., 2015; García-Ruiz et al., 2015). Its
dysfunction could lead to insulin resistance and NAFLD. Many reports have demonstrated
that increased macrophages in adipose tissue are correlated with obesity (Lumeng and
Saltiel, 2011; Luo et al., 2015). Here we show that the consumption of a HFD led to an
increase in white adipose tissue inflammation and adiposity, however, GS showed sig-
nificantly reversed results. Forming crown-like structures because of macrophage infil-
tration in the adipose tissue is known for the main inducer of inflammation, and we
confirmed that GS significantly decrease the percentage of F4/80-positive cells per total
cells. In addition, when adipocytes are stimulated with toll-like receptors, they activate
NF-κB and p38 (Jiang et al., 2011), and we confirmed that GS significantly decreases their
protein levels. These results indicated that GS could ameliorate the adipose tissue in-
flammation induced by a HFD.
Brown adipose tissue is also related to the modulation of energy balance and thermo-
genesis induction, which are important for body weight maintenance and glucose ho-
meostasis (García-Ruiz et al., 2015). UCP-1 is a key component of thermogenesis and is
used as the brown adipocyte-specific gene marker. Several studies showed that HFD
increased the thermogenic capacity, which can lead to the maintenance of body weight and
the dissipation of excess energy intake. We confirmed that HFD significantly decreased
UCP-1 expression in white adipose tissue, but increased in brown adipose tissue relative
to the CON group. Protein levels also showed opposite results in white and brown









































































































adipose tissue. This result supports the findings of previous studies, and indicates that HFD
acts as stimulus for the activation of brown adipose tissue. White adipose tissue browning
induction can also prevent an increase energy waste (García-Ruiz et al., 2015). Our data
showed that GS could reverse browning in white adipose tissue.
Furthermore, we investigated the cytokines in white adipose tissue: leptin and adipo-
nectin. Leptin is a key factor in regulating energy intake and expenditure, and it is well
known that decreased leptin synthesis is associated with lipolysis (Qureshi and Abrams,
2007; Mopuri et al., 2015). Adiponectin is an adipocyte-specific protein and is well known
to regulate insulin sensitivity and glucose homeostasis (Tolman et al., 2007). Our study
demonstrated that GS significantly lowered the leptin levels and improved the mRNA
expression levels. Taken together, GS could effectively improve adiposity and inflamma-
tion in adipose tissue as well as energy homeostasis.
Since NAFLD has also been linked to obesity, we investigated whether GS could
improve the liver steatosis induced by a HFD (Tarantino et al., 2010; Luo et al., 2015). GS
was found to effectively alleviate the NAS and TG levels in the liver; serum AST and ALT
levels were used as markers of liver damage (Strauss et al., 2000; Kim et al., 2016). Sirius
red staining and F4/80 IHC of the liver, protein and mRNA levels indicated that GS could
effectively improve the NAFLD induced by a HFD.
In conclusion, our data support the acute hyperglycemic effect of GS in the postprandial
state, as well as, the existence of a relationship between insulin resistance, and the dys-
function of adipose tissue and the liver induced by a HFD. GS demonstrated preventative
effects against HFD-induced metabolic disorders when it was used as a functional dietary
supplement in this study. However, further studies are needed to investigate the relation-
ship between its antisweet property and food intake in a pair-wise feeding study in order to
investigate the control of food intake and its beneficial effect.
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Supplementary Figure 1. HPLC chromatogram of (A) deacyl gymnemic acid and (B) estimation of gymnemic
acids as deacyl gymnemic acid.









































































































Table S1. Description of Gymnema Sylvestre Extract
Physical Profile
Particle size 80 Mesh: 90%, 40 Mesh: 95%
Loose density 0.30–0.70 g/ml
Bulk density 0.64 g/ml
Product profile
Identification To pass by TLC
Loss on drying 3.6%
Residual solvent <50.00 ppm
Assay
Gymnemic Acid by HPLC (as Deacylgymnemic acid) 10.2 (% w/w)
Total gymnemic Acid by Gravimetry 25.4 (% w/w)
Table S2. Experimental Diet Composition and Energy Contents
HFD+GS(mg/kg body weight)
Macronutrients CON HFD 100 250 500
Carbohydrate (%) 70.00 20.00 20.00 20.00 20.00
Protein (%) 20.00 20.00 20.00 20.00 20.00
Fat (%) 10.00 60.00 60.00 60.00 60.00
Ingredients (g/kg)
Casein 189.56 258.45 258.11 257.62 256.79
L-Cystine 2.84 3.88 3.87 3.86 3.85
Corn Starch 521.30 — — — —
Maltodextrin 142.17 161.53 161.32 161.01 160.49
Sucrose — 88.91 88.79 88.62 88.34
Cellulose 47.39 64.61 64.53 64.40 64.20
Soybean Oil 23.70 32.31 32.26 32.20 32.10
Lard 18.96 316.60 316.19 315.58 314.57
Mineral Mix 9.48 12.92 12.91 12.88 12.84
DiCalcium Phosphate 12.32 16.80 16.78 16.75 16.69
Calcium Citrate 5.21 7.11 7.10 7.08 7.06
Potassium Citrate 15.64 21.32 21.29 21.25 21.19
Vitamin Mix 9.48 12.92 12.91 12.88 12.84
Choline Bitartrate 1.90 2.58 2.58 2.58 2.57
Gymnema sylvestre extract — — 1.29 3.22 6.42









































































































Table S3. Primer Sequences for qRT-PCR
Name Forward Reverse
TNF-α 5 0-CACGTCGTAGCAAACCACCAAGTGGA-3 0 5 0TGGGAGTAGACAAGGTACAACCC-3 0
TGF-β 5 0-GACCGCAACAACGCCATCTA-3 0 5 0-GGCGTATCAGTGGGGGTCAG-3 0
FAS 5 0-GGGACAGGACAAGACAAAAAGGG-3 0 5 0-AGCCACGAGTGAGTGTACGGGAG-3 0
Leptin 5 0-ATGTGGTACGGAAGGTGGAG-3 0 5 0-TGGCTACCTTCGTCTGTGTG-3 0
Adiponectin 5 0-TGTTGGAATGACAGGAGCTGAA-3 0 5 0-CACACTGAAGCCTGAGCGATAC-3 0
SREBP-1c 5 0-TAGAGCATATCCCCCAGGTG-3 0 5 0-GGTACGGGCCACAAGAAGTA-3 0
IL-6 5 0-GTCCTTCAGAGAGATACAGAAAC-3 0 5 0-GCTCCTTAGCCACTCCTT-3 0
GAPDH 5 0-CGTGCCGCCTGGAGAAACC-3 0 5 0-TGGAAGAGTGGGAGTTGCTGTTG-3 0
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